This is a demo store. No orders will be fulfilled.

首页   400-620-6333
  • 登录
  • 注册
  • 英文站
切换导航
我的购物车
搜索
高级搜索
菜单
登录
设置
྾

伏格列波糖, α-葡萄糖苷酶抑制剂

α-葡萄糖苷酶抑制剂
1篇引用文献 COA COA
    级别和纯度:
  • ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
V121714-5mg
 5mg 期货 Stock Image
V121714-25mg
 25mg 期货 Stock Image
V121714-50mg
 50mg 现货 Stock Image
V121714-100mg
 100mg 现货 Stock Image
V121714-500mg
 500mg 现货 Stock Image
大包装询价 收藏夹 比较  SDS下载  DATASHEET  质量标准
查看相关系列
Glucose Metabolism (3713) Glucosidase (71) Metabolic Enzyme/Protease (4889) 药物成分 (367)
main product photo

基本描述

别名 伏格列波糖
英文别名 A25630 | D01665 | DTXSID2021442 | HMS3678A17 | 3,4-Dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol | A872822 | NCGC00164595-01 | (1S,2S,3R,4S,5S)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3
规格或纯度 ≥98%
英文名称 Voglibose
生化机理 口服有效α-葡萄糖苷酶抑制剂（蔗糖酶和麦芽糖酶的IC50值分别为3.9和6.4 nM）。在Wistar肥胖大鼠中增加胰高血糖素样肽1（GLP-1）的分泌并减少食物摄入量，并降低血浆葡萄糖，甘油三酸酯和胰岛素的浓度。在体内表现出抗糖尿病和抗肥胖活性。
应用 伏格列波糖是一种α-葡萄糖苷酶抑制剂,与阿卡波糖(acarbose)，米格列醇(miglitol)类似，用于降低糖尿病人餐后高血糖（PPHG）。伏格列波糖是用来作为胰高血糖素样肽受体和磷酸肌醇3 - 激酶Akt内皮型一氧化氮合酶路径对缺血再灌注损伤的一种保护剂.
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 抑制剂
作用机制 α-葡萄糖苷酶抑制剂
产品介绍

伏格列波糖是一种α-葡萄糖苷酶抑制剂,与阿卡波糖(acarbose)，米格列醇(miglitol)类似，用于降低糖尿病人餐后高血糖（PPHG）。伏格列波糖是用来作为胰高血糖素样肽受体和磷酸肌醇3 - 激酶Akt内皮型一氧化氮合酶路径对缺血再灌注损伤的一种保护剂.

Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through Glukagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.
Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through Glukagon-like peptide receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.
纯度 ≥98%

关联靶点（人）

GAA Tclin 溶酶体α-葡萄糖苷酶(Lysosomal alpha-glucosidase) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
MGAM Tclin Maltase-glucoamylase (654 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
PGR Tclin Progesterone receptor (8562 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
AR Tclin Androgen Receptor (11781 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
GABRA1 Tclin GABA receptor alpha-1 subunit (399 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
AVPR2 Tclin Vasopressin V2 receptor (2912 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
AGTR1 Tclin Type-1 angiotensin II receptor (5176 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
KCNH2 Tclin HERG (29587 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CACNA1C Tclin Voltage-gated L-type calcium channel alpha-1C subunit (766 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
PDE3A Tclin Phosphodiesterase 3A (3309 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADRA2C Tclin Alpha-2c adrenergic receptor (4876 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
TBXA2R Tclin Thromboxane A2 receptor (5717 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADORA2A Tclin Adenosine A2a receptor (16305 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ADORA3 Tchem Adenosine A3 receptor (15931 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BDKRB2 Tclin Bradykinin B2 receptor (3970 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HRH3 Tclin Histamine H3 receptor (10389 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CHRNA4 Tclin Neuronal acetylcholine receptor protein alpha-4 subunit (1265 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

关联靶点（其它种属）

Mc4r Melanocortin receptor 4 (1205 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Cckar Cholecystokinin A receptor (90 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Pde4d Phosphodiesterase 4D (4 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Hdac6 Histone deacetylase 6 (222 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Lct Lactase-glycosylceramidase (87 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Gaa Acidic alpha-glucosidase (551 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Rattus norvegicus (775804 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

PubChem SID 504758820
分子类型 小分子
IIUPAC Name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
INCHI 1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
InChi Key FZNCGRZWXLXZSZ-CIQUZCHMSA-N
Smiles C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
Isomeric SMILES C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
PubChem CID 444020
分子量 267.28
Reaxy-Rn 5430708

化学和物理性质

溶解性 溶于water, 最高浓度 (mg/mL): 26.73, 最高浓度(mM): 100；溶于DMSO, 最高浓度 (mg/mL): 20.05, 最高浓度(mM): 75
敏感性 对热敏感
比旋光度 46°(C=1,0.1mol/L HCL)
熔点 165°C
分子量 267.280 g/mol
XLogP3 -4.100
氢键供体数Hydrogen Bond Donor Count 8
氢键受体数Hydrogen Bond Acceptor Count 8
可旋转键计数Rotatable Bond Count 5
精确质量Exact Mass 267.132 Da
单同位素质量Monoisotopic Mass 267.132 Da
拓扑极表面积Topological Polar Surface Area 154.000 Ų
重原子数Heavy Atom Count 18
形式电荷Formal Charge 0
复杂度Complexity 263.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 5
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

安全和危险性（GHS）

WGK Germany 3
RTECS NM7524600
Merck Index 10029

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number) 证书类型 货号
H2106246 分析证书 V121714
H2106247 分析证书 V121714
A2411840 分析证书 V121714
A2411841 分析证书 V121714
A2411839 分析证书 V121714
H2106248 分析证书 V121714

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. T Hara,N Hotta.  (1998-01-22)  [Voglibose]..  Nihon rinsho. Japanese journal of clinical medicine,  55 Suppl  (114-119).  [PMID:9434453]
2. Jiro Nakamura.  (2005-03-23)  [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]..  Nihon rinsho. Japanese journal of clinical medicine,  63 Suppl 2  (457-461).  [PMID:15779422]
3. Ryuzo Kawamori.  (2010-05-08)  [Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance]..  Nihon rinsho. Japanese journal of clinical medicine,  68  ((5)): (873-881).  [PMID:20446586]
4. Y Iwamoto,A Kashiwagi,N Yamada,S Terao,N Mimori,M Suzuki,H Tachibana.  (2010-07-02)  Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study..  Diabetes, obesity & metabolism,  12  ((8)): (700-708).  [PMID:20590747]
5. Yasuhiro Shimojima,Wataru Ishii,Masayuki Matsuda,Kana Tojo,Rie Watanabe,Shu-Ichi Ikeda.  (2011-01-18)  Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review..  Modern rheumatology,  21  ((4)): (415-419).  [PMID:21240619]
6. R Kawamori,N Inagaki,E Araki,H Watada,N Hayashi,Y Horie,A Sarashina,Y Gong,M von Eynatten,H J Woerle,K A Dugi.  (2011-12-08)  Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study..  Diabetes, obesity & metabolism,  14  ((4)): (348-357).  [PMID:22145698]
7. Michio Shimabukuro,Hiroaki Masuzaki,Masataka Sata.  (2012-02-02)  Intensive glucose lowering in cardiovascular risk management - unsolved questions - ..  Circulation journal : official journal of the Japanese Circulation Society,  76  ((3)): (593-595).  [PMID:22293455]
8. Devasier Bennet,Mohana Marimuthu,Sanghyo Kim,Jeongho An.  (2012-08-14)  Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery..  International journal of nanomedicine,  7  (3399-3419).  [PMID:22888222]
9. Masahiro Inoue.  (2012-09-22)  Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus..  Expert opinion on pharmacotherapy,  13  ((16)): (2257-2268).  [PMID:22994875]
10. E Araki,R Kawamori,N Inagaki,H Watada,N Hayashi,Y Horie,A Sarashina,S Thiemann,M von Eynatten,K Dugi,H-J Woerle.  (2012-11-21)  Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes..  Diabetes, obesity & metabolism,  15  ((4)): (364-371).  [PMID:23163910]
11. Yuri Ono,Hiraku Kameda,Kyu Yong Cho.  (2013-02-19)  Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus..  Expert opinion on pharmacotherapy,  14  ((4)): (361-370).  [PMID:23414242]
12. Chiaki Seo,Masaya Sakamoto,Rimei Nishimura,Daisuke Tsujino,Kiyotaka Ando,Aya Morimoto,Kazunori Utsunomiya.  (2013-05-03)  Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study..  Diabetes technology & therapeutics,  15  ((5)): (378-385).  [PMID:23634671]
13. Bum-Ho Bin,Juyeon Seo,Seung Ha Yang,Eunkyung Lee,Hyunjung Choi,Kyu-Han Kim,Eun-Gyung Cho,Tae Ryong Lee.  (2013-07-25)  Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis..  Experimental dermatology,  22  ((8)): (541-546).  [PMID:23879813]
14. Hyun Ju Do,Taeon Jin,Ji Hyung Chung,Ji Won Hwang,Min-Jeong Shin.  (2014-01-07)  Voglibose administration regulates body weight and energy intake in high fat-induced obese mice..  Biochemical and biophysical research communications,  443  ((3)): (1110-1117).  [PMID:24388987]
15. Chikoto Hashiguchi,Shin-ichiro Kawamoto,Takayuki Kasai,Yasuhiro Nishi,Eiichi Nagaoka.  (2014-05-23)  Influence of an antidiabetic drug on biomechanical and histological parameters around implants in type 2 diabetic rats..  Implant dentistry,  23  ((3)): (264-269).  [PMID:24844386]
16. Toshiyuki Takasu,Yuka Hayashizaki,Atsuo Tahara,Eiji Kurosaki,Shoji Takakura.  (2014-10-15)  Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter\xa02 inhibitor, in combination with oral antidiabetic drugs in mice..  Clinical and experimental pharmacology & physiology,  42  ((1)): (87-93).  [PMID:25311502]
17. Hyang-Ki Choi,Minkyung Oh,Eun Ji Kim,Geun Seog Song,Jong-Lyul Ghim,Ji-Hong Shon,Ho-Sook Kim,Jae-Gook Shin.  (2014-12-30)  Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin..  International journal of clinical pharmacology and therapeutics,  53  ((2)): (147-153).  [PMID:25546164]
18. Hiroki Oe,Kazufumi Nakamura,Hajime Kihara,Kenei Shimada,Shota Fukuda,Tsutomu Takagi,Toru Miyoshi,Kumiko Hirata,Junichi Yoshikawa,Hiroshi Ito.  (2015-06-19)  Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial..  Cardiovascular diabetology,  14  (83-83).  [PMID:26084668]
19. Atsuo Tahara,Toshiyuki Takasu,Masanori Yokono,Masakazu Imamura,Eiji Kurosaki.  (2015-10-10)  Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice..  Archives of pharmacal research,  39  ((2)): (259-270).  [PMID:26450351]
20. Kenji Akahane,Kazuma Ojima,Ayaka Yokoyama,Toshihiro Inoue,Sumiyoshi Kiguchi,Satoshi Tatemichi,Hiroo Takeda,Yohsuke Imai.  (2017-07-27)  Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats..  Clinical and experimental pharmacology & physiology,  44  ((12)): (1263-1271).  [PMID:28744906]
21. Xiaodan Liu,Jianan Feng,Yan Li.  (2018-03-05)  Preparation of carbon-functionalized magnetic graphene/mesoporous silica composites for selective extraction of miglitol and voglibose in rat plasma..  Talanta,  182  (405-413).  [PMID:29501171]
22. Kemin Tan,Christine Tesar,Rosemarie Wilton,Robert P Jedrzejczak,Andrzej Joachimiak.  (2018-05-16)  Interaction of antidiabetic α-glucosidase inhibitors and gut bacteria α-glucosidase..  Protein science : a publication of the Protein Society,  27  ((8)): (1498-1508).  [PMID:29761590]
23. R M Coleman,G Ojeda-Torres,W Bragg,D Fearey,P McKinney,L Castrodale,D Verbrugge,K Stryker,E DeHart,M Cooper,E Hamelin,J Thomas,R C Johnson.  (2018-05-26)  Saxitoxin Exposure Confirmed by Human Urine and Food Analysis..  Journal of analytical toxicology,  42  ((7)): (e61-e64).  [PMID:29800291]
24. Atsuo Tahara,Yoshinori Kondo,Toshiyuki Takasu,Hiroshi Tomiyama.  (2018-07-20)  Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats..  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,  105  (1033-1041).  [PMID:30021338]
25. Zhi Xiang Ng,Nureen Farhana Rosman.  (2019-03-25)  In vitro digestion and domestic cooking improved the total antioxidant activity and carbohydrate-digestive enzymes inhibitory potential of selected edible mushrooms..  Journal of food science and technology,  56  ((2)): (865-877).  [PMID:30906044]
26. Mai Sotoyama,Shinya Uchida,Chiaki Kamiya,Shimako Tanaka,Yasuharu Kashiwagura,Akio Hakamata,Keiichi Odagiri,Naoki Inui,Hiroshi Watanabe,Noriyuki Namiki.  (2019-06-04)  Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets..  Chemical & pharmaceutical bulletin,  67  ((6)): (540-545).  [PMID:31155559]
27. Shipra Bhansali,Anil Bhansali,Pinaki Dutta,Rama Walia,Veena Dhawan.  (2020-01-25)  Metformin upregulates mitophagy in patients with T2DM: A randomized placebo-controlled study..  Journal of cellular and molecular medicine,  24  ((5)): (2832-2846).  [PMID:31975558]
28. Junichi Kato,Yohei Shirakami,Taku Mizutani,Masaya Kubota,Hiroyasu Sakai,Takashi Ibuka,Masahito Shimizu.  (2020-03-27)  Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice..  International journal of molecular sciences,  21  ((6)): [PMID:32210144]
29. Xiaolong Chen,Yuguo Zheng,Yinchu Shen.  (2006-02-07)  Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors..  Current medicinal chemistry,  13  ((1)): (109-116).  [PMID:16457643]
30. Makoto Hiki,Kazunori Shimada,Takashi Kiyanagi,Kosuke Fukao,Kuniaki Hirose,Hiromichi Ohsaka,Yoshifumi Fukushima,Atsumi Kume,Rie Matsumori,Katsuhiko Sumiyoshi,Tetsuro Miyazaki,Hirotoshi Ohmura,Takeshi Kurata,Takashi Miida,Hiroyuki Daida.  (2010-06-04)  Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -..  Circulation journal : official journal of the Japanese Circulation Society,  74  ((7)): (1471-1478).  [PMID:20519875]
31. Y Iwamoto,N Tajima,T Kadowaki,K Nonaka,T Taniguchi,M Nishii,J C Arjona Ferreira,J M Amatruda.  (2010-07-02)  Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial..  Diabetes, obesity & metabolism,  12  ((7)): (613-622).  [PMID:20590736]
32. Xiu-mei Dai,Ning An,Jian-min Wu,Hui-yi Li,Qi-ming Zhang.  (2011-02-26)  Development and validation of HPLC-UV-MS method for the control of four anti-diabetic drugs in suspected counterfeit products..  Yao xue xue bao = Acta pharmaceutica Sinica,  45  ((3)): (347-352).  [PMID:21348424]
33. Keisuke Fujitaka,Hajime Otani,Fusakazu Jo,Hiromi Jo,Emiko Nomura,Masayoshi Iwasaki,Mitsushige Nishikawa,Toshiji Iwasaka.  (2011-04-19)  Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome..  Endocrine journal,  58  ((6)): (425-432).  [PMID:21498915]
34. Ryuzo Kawamori.  (2011-07-20)  [Evidence demonstrating the effect of voglibose for the prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese subjects with inpaired glucose tolerance]..  Nihon rinsho. Japanese journal of clinical medicine,  69 Suppl 1  (663-670).  [PMID:21766678]
35. T Narita,H Yokoyama,R Yamashita,T Sato,M Hosoba,T Morii,H Fujita,K Tsukiyama,Y Yamada.  (2011-11-05)  Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients..  Diabetes, obesity & metabolism,  14  ((3)): (283-287).  [PMID:22051162]
36. Yu Kataoka,Satoshi Yasuda,Yoshihiro Miyamoto,Kazuhiro Sase,Masami Kosuge,Kazuo Kimura,Yasunao Yoshimasa,Shunichi Miyazaki.  (2012-01-14)  Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients..  Circulation journal : official journal of the Japanese Circulation Society,  76  ((3)): (712-720).  [PMID:22240597]
37. Eberhard Standl,Oliver Schnell.  (2012-04-18)  Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation..  Diabetes & vascular disease research,  9  ((3)): (163-169).  [PMID:22508699]
38. Tomoko Kimura,Jinya Suzuki,Mai Ichikawa,Michiko Imagawa,Satsuki Sato,Miki Fujii,Yasuo Zenimaru,Satoru Inaba,Sadao Takahashi,Tadashi Konoshita,Isamu Miyamori.  (2012-04-24)  Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50..  Diabetes technology & therapeutics,  14  ((7)): (545-551).  [PMID:22519736]
39.  (2012-09-29)  Intestinal alpha-glucosidase inhibitors: abdominal gas cysts..  Prescrire international,  21  ((130)): (212-213).  [PMID:23016254]
40. Makoto Ayaori,Naotsugu Iwakami,Harumi Uto-Kondo,Hiroki Sato,Makoto Sasaki,Tomohiro Komatsu,Maki Iizuka,Shunichi Takiguchi,Emi Yakushiji,Kazuhiro Nakaya,Makiko Yogo,Masatsune Ogura,Bonpei Takase,Takehiko Murakami,Katsunori Ikewaki.  (2013-03-26)  Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients..  Journal of the American Heart Association,  2  ((1)): (e003277-e003277).  [PMID:23525426]
41. Masayuki Yamaguchi,Takami Saji,Sachiko Mita,Kenneth Kulmatycki,Yan-Ling He,Kenichi Furihata,Kaneo Sekiguchi.  (2013-06-21)  Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes..  International journal of clinical pharmacology and therapeutics,  51  ((8)): (641-651).  [PMID:23782587]
42. Ho-Sook Kim,Minkyung Oh,Eun Ji Kim,Geun Seog Song,Jong-Lyul Ghim,Ji-Hong Shon,Dong-Hyun Kim,Jae-Gook Shin.  (2014-08-28)  Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects..  International journal of clinical pharmacology and therapeutics,  52  ((11)): (1005-1011).  [PMID:25161160]
43. Kaoru Noguchi,Minoru Hirota,Toru Miyoshi,Yoshinori Tani,Yoko Noda,Hiroshi Ito,Seiji Nanba.  (2014-12-03)  Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals..  Experimental and therapeutic medicine,  9  ((1)): (84-88).  [PMID:25452780]
44. Clement Lo,Tadashi Toyama,Ying Wang,Jin Lin,Yoichiro Hirakawa,Min Jun,Alan Cass,Carmel M Hawley,Helen Pilmore,Sunil V Badve,Vlado Perkovic,Sophia Zoungas.  (2018-09-25)  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease..  The Cochrane database of systematic reviews,  9  (CD011798-CD011798).  [PMID:30246878]
45. Ji-Won Kim,Ye-Jee Lee,Young-Hye You,Min Kyong Moon,Kun-Ho Yoon,Yu-Bae Ahn,Seung-Hyun Ko.  (2018-11-27)  Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes..  Journal of cellular biochemistry,  [PMID:30474134]
46. Jin Bong Choi,Je Mo Yoo,Ye-Jee Lee,Jae Woong Kim,Seung-Ju Lee,Hee Youn Kim,Dong Sup Lee,Seung-Hyun Ko,Hyun-Sop Choe.  (2020-04-07)  Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes..  International neurourology journal,  24  ((1)): (21-28).  [PMID:32252183]
47. Kentaro Ejiri,Toru Miyoshi,Hajime Kihara,Yoshiki Hata,Toshihiko Nagano,Atsushi Takaishi,Hironobu Toda,Seiji Nanba,Yoichi Nakamura,Satoshi Akagi,Satoru Sakuragi,Taro Minagawa,Yusuke Kawai,Nobuhiro Nishii,Soichiro Fuke,Masaki Yoshikawa,Kazufumi Nakamura,Hiroshi Ito.  (2020-08-18)  Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus..  Journal of the American Heart Association,  9  ((16)): (e015103-e015103).  [PMID:32805185]
48. Pooja Shah,Vishal Chavda,Snehal Patel,Shraddha Bhadada,Ghulam Md Ashraf.  (2020-10-16)  Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies..  Current gene therapy,  20  ((3)): (223-235).  [PMID:33054705]
49. Donghui Wu, Qilin Zhao, Bing Zhang, Xianqing Tang, Yushu Li, Jian Sun, Xiurong Yang.  (2024)  Iron-Doped Polymer Dots with Enhanced Fluorescence and Dual Enzyme Activity for Versatile Bioassays.  ANALYTICAL CHEMISTRY,  96  (7): (2929-2938).  [PMID:38324754] [10.1021/acs.analchem.3c04514]

溶液计算器

上海阿拉丁生化科技股份有限公司
© 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

上海工商 危险品化学品经营许可证（带存储）营业执照(三证合一)